Certara, Inc. Common Stock CERT

Certara, Inc. es un proveedor de software de biosimulación y servicios habilitados por tecnología. La empresa se enfoca en producir medicamentos para pacientes utilizando software de biosimulación, tecnología y servicios para transformar el descubrimiento y desarrollo de medicamentos tradicional. La empresa construye su tecnología de biosimulación en los primeros principios de biología, química y farmacología con algoritmos matemáticos que modelan cómo se comportan los medicamentos y las enfermedades en el cuerpo. Ofrece una plataforma integrada de extremo a extremo para sus clientes, incluidas varias compañías biofarmacéuticas, instituciones académicas y agencias reguladoras en 62 países. También proporciona una plataforma impulsada por inteligencia artificial para que las organizaciones integren y analicen contenido en todo su panorama de datos empresariales. Tiene operaciones en Estados Unidos, Australia, Canadá, China, Francia, Alemania, India, Italia, Japón, Luxemburgo, Países Bajos, Filipinas, Polonia, Portugal, España, Suiza y Reino Unido.

• GlobeNewswire Inc. 23 sept

  Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine Demand

  The global biosimulation market reached USD 4.09 billion in 2025 and is projected to grow at 16.90% CAGR through 2035, reaching USD 19.49 billion. Growth is driven by AI-driven drug discovery, virtual clinical trials, personalized medicine demand, and computational modeling adoption. However, geopolitical instability in the Middle East has created near-term supply chain disruptions and increased pharmaceutical packaging costs by 15-20%. Key players are pursuing strategic acquisitions and platform launches to expand capabilities.

  

• GlobeNewswire Inc. 3 sept

  The Market Just Told You Which Layer Of AI Biology It Is Paying For

  Recent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.

  

• GlobeNewswire Inc. 26 jun

  [Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

  The global in silico clinical trials market, valued at USD 1.84 billion in 2025, is projected to grow to USD 8.94 billion by 2035 at a 15.2% CAGR. Growth is driven by high failure rates in traditional clinical trials, regulatory acceptance of computational evidence, advances in AI and digital twins, and ethical concerns about animal testing. North America dominates the market while Asia Pacific shows the fastest growth.

  

• GlobeNewswire Inc. 19 jun

  Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm

  Law firm Bragar Eagel & Squire is investigating Certara, Inc. for potential securities law violations following the company's Q1 2026 earnings announcement. Certara reported declining services revenue (down 4% YoY to $57.2M) and bookings (down 14% YoY to $66.6M), citing softer performance from major customers and exiting its regulatory business. The stock fell 19% on the news, dropping from $6.31 to $5.13 per share on May 11, 2026.

  

• GlobeNewswire Inc. 18 jun

  Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

  Law firm Johnson Fistel is investigating Certara, Inc. (NASDAQ: CERT) on behalf of investors who suffered losses following the company's May 2026 earnings report disclosing declining services revenue and bookings, along with execution challenges. The investigation was further prompted by the announcement of CFO John Gallagher's resignation effective July 14, 2026. Investors who purchased Certara securities and experienced losses are encouraged to contact the firm.